Skip to main content
. 2016 Sep 8;6:33116. doi: 10.1038/srep33116

Figure 2. b-AP15 decreases Smad2 and Smad3 levels in HLF, Mrc5, and MLE12 cells.

Figure 2

(A) HLF cells were treated with b-AP15 (10 μM) for 0–2 h. Cell lysates were analyzed by immunoblotting with the antibodies to Smad2, Smad3, Smad7, ALK5, UCHL5, and β-actin. (B) HLF cells were treated with different doses of b-AP15 (0, 1, 5, 10, and 25 μM) and IU1 (100 μM) for 30 min and 120 min. Cell lysates were analyzed by immunoblotting with the antibodies to Smad2, Smad3, and β-actin. (C) MRC5 cells were treated with different doses of b-AP15 (0, 1, 2.5, 5, and 10 μM) and IU1 (100 μM) for 1 h. Cell lysates were analyzed by immunoblotting with the antibodies to Smad2, Smad3, Smad7, ALK5, and β-actin. (D) MLE12 cells were treated with different doses of b-AP15 (0, 1, 2.5, 5, and 10 μM) for 1 h. Cell lysates were analyzed by immmunoblotting with the antibodies to Smad2, Smad3, UCHL5, and β-actin. Western blot images were cropped to improve the conciseness of the data; samples derived from the same experiment and the blots were processed in parallel. Representative of experiments performed at least 3 independent times.